[{"orgOrder":0,"company":"EyeCRO","sponsor":"InMed Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Controlled Substance","year":"2020","type":"Licensing Agreement","leadProduct":"Cannabinol","moa":"cannabinol derivatives","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"EyeCRO","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"EyeCRO \/ InMed Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"EyeCRO \/ InMed Pharmaceuticals"}]

Find Clinical Drug Pipeline Developments & Deals by EyeCRO

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmapack
                          Not Confirmed
                          Pharmapack
                          Not Confirmed

                          Details : The licensing agreement with EyeCRO grants InMed an exclusive, worldwide license to develop and commercialize prospective therapeutic formulations combining MiDROPS® with any and all cannabinoid molecules.

                          Product Name : Undisclosed

                          Product Type : Controlled Substance

                          Upfront Cash : Undisclosed

                          December 03, 2020

                          Lead Product(s) : Cannabinol

                          Therapeutic Area : Ophthalmology

                          Highest Development Status : Preclinical

                          Sponsor : InMed Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank